Cullinan Therapeutics Inc (CGEM)

$15.58

-0.9

(-5.46%)

Market is closed - opens 8 PM, 08 Nov 2024

Performance

  • $15.40
    $17.17
    $15.58
    downward going graph

    1.16%

    Downside

    Day's Volatility :10.31%

    Upside

    9.26%

    downward going graph
  • $7.64
    $30.19
    $15.58
    downward going graph

    50.96%

    Downside

    52 Weeks Volatility :74.69%

    Upside

    48.39%

    downward going graph

Returns

PeriodCullinan Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-0.36%
1.4%
0.0%
6 Months
-43.85%
3.8%
0.0%
1 Year
67.14%
15.3%
0.0%
3 Years
-30.02%
11.4%
-27.4%

Highlights

Market Capitalization
926.5M
Book Value
$11.34
Earnings Per Share (EPS)
-3.06
Wall Street Target Price
32.38
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.04%
Return On Equity TTM
-24.94%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
18.9M
EBITDA
-183.0M
Diluted Eps TTM
-3.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.26
EPS Estimate Next Year
-3.3
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
-0.73

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Cullinan Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 107.83%

Current $15.58
Target $32.38

Technicals Summary

Sell

Neutral

Buy

Cullinan Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cullinan Therapeutics  Inc
Cullinan Therapeutics Inc
2.74%
-43.85%
67.14%
-30.02%
-44.9%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cullinan Therapeutics  Inc
Cullinan Therapeutics Inc
9.03
NA
NA
-3.26
-0.25
-0.19
NA
11.34
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cullinan Therapeutics  Inc
Cullinan Therapeutics Inc
Buy
$923.0M
-44.9%
9.03
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Cullinan Therapeutics Inc

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 74.6%

Institutional Holdings

  • MPM Oncology Impact Management LP

    13.19%
  • Bvf Inc

    9.92%
  • BlackRock Inc

    6.12%
  • Deerfield Management Co

    5.66%
  • Vanguard Group Inc

    4.95%
  • Franklin Resources Inc

    4.22%

Company Information

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

Organization
Cullinan Therapeutics Inc
Employees
85
CEO
Mr. Nadim Ahmed
Industry
Other Consumer Services

FAQs